AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Update

AngioDynamics, Inc. (NASDAQ:ANGO) was the target of a significant drop in short interest during the month of October. As of October 31st, there was short interest totalling 1,230,000 shares, a drop of 16.9% from the October 15th total of 1,480,000 shares. Based on an average daily trading volume, of 479,100 shares, the short-interest ratio is presently 2.6 days.

Insider Buying and Selling

In other news, CEO James C. Clemmer acquired 20,000 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were acquired at an average cost of $6.03 per share, for a total transaction of $120,600.00. Following the purchase, the chief executive officer now owns 681,582 shares of the company’s stock, valued at approximately $4,109,939.46. The trade was a 3.02 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last 90 days, insiders purchased 22,568 shares of company stock worth $135,847. Insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On AngioDynamics

A number of large investors have recently bought and sold shares of the stock. Geode Capital Management LLC grew its holdings in AngioDynamics by 5.1% in the 3rd quarter. Geode Capital Management LLC now owns 960,767 shares of the medical instruments supplier’s stock worth $7,477,000 after acquiring an additional 46,409 shares during the last quarter. Barclays PLC grew its stake in shares of AngioDynamics by 81.0% in the third quarter. Barclays PLC now owns 83,582 shares of the medical instruments supplier’s stock worth $651,000 after purchasing an additional 37,394 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new position in AngioDynamics during the 3rd quarter valued at about $280,000. XTX Topco Ltd bought a new position in AngioDynamics during the 3rd quarter valued at approximately $582,000. Finally, State Street Corp lifted its holdings in AngioDynamics by 2.7% in the 3rd quarter. State Street Corp now owns 810,372 shares of the medical instruments supplier’s stock worth $6,305,000 after buying an additional 21,218 shares during the period. 89.43% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Canaccord Genuity Group lowered their price target on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, October 4th. HC Wainwright reissued a “buy” rating and set a $14.00 target price on shares of AngioDynamics in a report on Friday, October 4th.

AngioDynamics Trading Down 0.6 %

Shares of NASDAQ ANGO opened at $6.81 on Friday. AngioDynamics has a 12 month low of $5.26 and a 12 month high of $8.25. The firm has a market capitalization of $276.72 million, a price-to-earnings ratio of -1.12 and a beta of 0.67. The business has a 50-day moving average of $7.00 and a 200-day moving average of $6.76.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. The firm had revenue of $67.50 million for the quarter, compared to analyst estimates of $67.93 million. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The business’s revenue for the quarter was down 14.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.12) EPS. On average, analysts predict that AngioDynamics will post -0.41 earnings per share for the current year.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.